A5049254392- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Molecular Biology Techniques and Applications
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Breast Implant and Reconstruction
- Bone health and treatments
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Breast Lesions and Carcinomas
- Reconstructive Surgery and Microvascular Techniques
- Cancer Cells and Metastasis
- Computational Drug Discovery Methods
- Hair Growth and Disorders
- Chemotherapy-related skin toxicity
- Radiopharmaceutical Chemistry and Applications
- Cancer survivorship and care
- PI3K/AKT/mTOR signaling in cancer
- Gastric Cancer Management and Outcomes
- Bone Metabolism and Diseases
Innsbruck Medical University
2016-2025
Universität Innsbruck
2016-2025
Austrian Breast & Colorectal Cancer Study Group
2016-2025
Tirol Kliniken
2025
Medical University of Vienna
2016-2025
BrustGesundheitZentrum Tirol
2017-2024
Universitätsklinik für Frauenheilkunde und Geburtshilfe
2009-2023
University Hospital Innsbruck
2014-2023
Medical University of Graz
2016-2019
Comprehensive Cancer Center Vienna
2016-2019
Abstract Immune checkpoint blockade (ICB) benefits some patients with triple-negative breast cancer, but what distinguishes responders from non-responders is unclear 1 . Because ICB targets cell–cell interactions 2 , we investigated the impact of multicellular spatial organization on response, and explored how remodels tumour microenvironment. We show that cell phenotype, activation state location are intimately linked, influence effect differ in sensitive versus resistant tumours early...
For postmenopausal women with hormone-receptor-positive breast cancer, the most effective duration for adjuvant therapy an aromatase inhibitor remains unclear.In this prospective, phase 3 trial, we randomly assigned cancer who had received 5 years of endocrine to receive anastrozole additional 2 (2-year group, receiving a total 7 years) or (5-year 10 years). The primary end point was disease-free survival. analysis included all patients were still participating in trial and no recurrence...
Abstract Background About 50% of all primary breast cancers show a low-level expression HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack gene amplification measured by in situ hybridization. This low is promising new target for antibody–drug conjugates (ADCs) currently under investigation. Until now, little known about the frequency prognostic value HER2-expression metastatic cancer (MBC). Patients methods The MBC-Registry Austrian Study Group Medical Tumor Therapy (AGMT)...
Patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC) have low pathological complete response (pCR) rates neoadjuvant chemotherapy. A subset of ER+/HER2- BC contains dense lymphocytic infiltration. We hypothesized that addition an anti-programmed death 1 agent may increase pCR in this subtype. conducted a randomized, multicenter, double-blind phase 3 trial to investigate the benefit adding nivolumab chemotherapy...
Abstract Background: Triple negative breast cancers of high proliferation or grade are a subgroup characterized by very poor prognosis, rapid progression to metastatic stage and onset resistance chemotherapy after initial response. As whole, triple cancer (TNBC) represents specific area medical need, in which new therapeutic approaches deserve appropriate test. Retrospective data showed that subset patients have an ongoing immune response within the tumor microenvironment, PD-L1 expression...
<h3>Importance</h3> Standard dosing of chemotherapy based on body surface area results in marked interpatient variation pharmacokinetics, toxic effects, and efficacy. Whether tailored can improve outcomes is unknown, as the role dose-dense adjuvant chemotherapy. <h3>Objective</h3> To determine whether improves early breast cancer compared with a standard 3-weekly schedule. <h3>Design, Setting, Participants</h3> A randomized, open-label, phase 3 trial women aged 65 years younger who had...
Addition of alpelisib to fulvestrant significantly extended progression-free survival in PIK3CA-mutant, hormone receptor-positive (HR+) advanced/metastatic breast cancer the phase III SOLAR-1 study. The combination and letrozole also had promising activity I studies HR+ cancer. NEO-ORB aimed determine whether addition could increase response rates neoadjuvant setting.Patients Methods: Postmenopausal women with HR+, human epidermal growth factor receptor 2-negative, T1c-T3 were assigned...
Medication-related osteonecrosis of the jaw (MRONJ) is one most important toxicities antiresorptive therapy, which standard practice for patients with breast cancer and bone metastases. However, population-based incidence MRONJ not well established. We therefore performed a retrospective multicenter study to assess whole Austrian federal state (Tyrol).
We developed tailored axillary surgery (TAS) to reduce the tumor volume in patients with clinically node-positive breast cancer point where radiotherapy can control it. The aim of this study was quantify extent load reduction achieved by TAS.
Accurate response assessment during neoadjuvant systemic treatment (NST) poses a clinical challenge. Therefore, minimally invasive of tumor based on cell-free circulating DNA (ctDNA) may be beneficial to guide decisions.
Importance The role of axillary lymph node dissection (ALND) to determine nodal burden inform systemic therapy recommendations in patients with clinically (cN)–positive breast cancer (BC) is currently unknown. Objective To address the association ALND cN-positive BC upfront surgery setting and after neoadjuvant chemotherapy (NACT). Design, Setting, Participants This was a prospective, observational, cohort study conducted from August 2018 June 2022. preplanned within phase 3 randomized...
Excessive fibrous capsule formation around silicone mammary implants (SMI) involves immune reactions to silicone. Capsular fibrosis, a common SMI complication linked host responses, worsens with specific implant topographies. Our study 10 patients investigated intra- and inter-individually, reduced surface roughness effects on disease progression, wound chronic inflammation, capsular composition. The results illuminate the significant impact of acute inflammatory fibrinogen accumulation,...
Toll‐like receptor 9 (TLR9) activates the innate immune response when exposed to non‐methylated CpG‐DNA. TLR9 was recently shown be expressed by cancer cells which have been previously characterized global hypomethylation. We set out examine expression and molecular activity of in breast ovarian cells. Firstly, we confirmed higher levels hypomethylated DNA serum patients with metastatic ( n = 18) versus age‐matched tumor‐free women 18). In cell lines tissues, mRNA associated...
The role of CHAC1 (cation transport regulator-like protein 1), a recently identified component the unfolded response (UPR) pathway, in gynaecological cancers has not yet been characterised. Now, this work illustrates mRNA expression and associated clinical outcome breast ovarian cancer. prognostic value its two transcript variants was investigated 116 133 tissues using quantitative real-time reverse-transcriptase PCR. Subsequently, we conducted functional studies short-interfering...
Abstract Background: Phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway activation is a hallmark hormone receptor-positive (HR+) breast cancer (BC) resistant to endocrine therapy (ET). Preclinical and clinical data suggest that adding PI3K inhibitor (PI3Ki) ET may overcome resistance. In BELLE-2, Phase III randomized study, buparlisib (BUP; BKM120; pan-PI3Ki) + fulvestrant (FULV) demonstrated activity manageable safety in patients (pts) with HR+, human...